12-months of Treatment With Burosumab in Children and Adolescents With X-linked Hypophosphatemia: a Prospective Longitudinal Cohort Study
Latest Information Update: 21 Sep 2022
At a glance
- Drugs Burosumab (Primary)
- Indications X-linked dominant hypophosphataemic rickets
- Focus Therapeutic Use
Most Recent Events
- 27 Aug 2021 Results published in the European Journal of Endocrinology
- 09 Jun 2020 New trial record